Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6743318 | 0.78 | KMT2A (0.35) | KMT2ASIGMAR1 | |
| SCHEMBL6743328 | 0.77 | MEN1 (0.38) | SLC6A3MEN1POLBGAAKMT2A | |
| SCHEMBL6053773 | 0.67 | SLC6A3 (0.57) | SLC6A3MEN1POLBGAAKMT2A | |
| SCHEMBL8673153 | 0.67 | SLC6A3 (0.57) | SLC6A3MEN1POLBGAAKMT2A | |
| SCHEMBL9467530 | 0.65 | MEN1 (0.47) | SLC6A3MEN1POLBGAAKMT2A | |
| SCHEMBL25732993 | 0.62 | KDM1A (0.53) | SLC6A3MEN1POLBGAAKMT2A | |
| SCHEMBL23339624 | 0.62 | MEN1 (0.49) | SLC6A3MEN1POLBGAAKMT2A | |
| SCHEMBL10080180 | 0.61 | MEN1 (0.35) | SLC6A3MEN1POLBGAAKMT2A | |
| SCHEMBL21896028 | 0.61 | L3MBTL1 (0.59) | SLC6A3MEN1POLBGAAKMT2A | |
| SCHEMBL10603938 | 0.61 | NPC1 (0.40) | SLC6A3MEN1POLBGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693153-B2 | USING COORDINATION CATALYST | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-02-17 | — | — | US | disclosed |
| US-20030139544-A1 | Catalyst system for the polymerization of alkenes to polyolefins | ENERGY, UNITED STATES DEPARTMENT OF | 2003-07-24 | — | — | US | disclosed |
| US-6469188-B1 | CATALYST SYSTEMS PARTICULARLY USEFUL FOR THE POLYMERIZATION OF POLYPROPYLENE TO GIVE ELASTOMERIC POLYPROPYLENES | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2002-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139544-A1 | Catalyst system for the polymerization of alkenes to polyolefins | MSH2, PMS2, SDC4 | SLC6A3 4594/4885MEN1 1486/4885POLB 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.